Akebia Ther (AKBA) - Stock Price & Dividends

Akebia Therapeutics, Inc. is a biopharmaceutical company focused on creating therapies to help patients with kidney diseases. Their primary focus is developing and bringing to the market Vafseo (vadadustat), an oral prolyl hydroxylase inhibitor, for treating anemia in adults with chronic kidney disease on dialysis or not. In addition to Vafseo, they also provide Auryxia, a ferric citrate used to regulate phosphorus levels in dialysis patients and treat iron deficiency anemia in non-dialysis CKD patients.

The company has formed partnerships with Mitsubishi Tanabe Pharma Corporation to distribute vadadustat in Japan and surrounding regions. They also have a research and license agreement with Janssen Pharmaceutica NV for the global development and commercialization of prolyl hydroxylase inhibitors for treating kidney diseases. Founded in 2007, Akebia Therapeutics, Inc. is centrally located in Cambridge, Massachusetts. For more information, you can visit their website at https://www.akebia.com.